Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.2K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.2K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

9.8K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
9.8K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.5K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.

Future oncology (London, England)·2026
Same author

Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment.

Neuro-oncology practice·2026
Same author

Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas.

JCO precision oncology·2026
Same author

Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association.

Stroke·2026
Same author

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma.

Neuro-oncology·2026
Same author

Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents.

Neuro-oncology practice·2025
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

18.7K

Primary CNS Lymphoma.

Christian Grommes1, Lisa M DeAngelis1

  • 1All authors: Memorial Sloan Kettering Cancer Center, New York, NY.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|June 23, 2017
PubMed
Summary
This summary is machine-generated.

Primary CNS lymphoma (PCNSL) treatment has improved with high-dose methotrexate, but outcomes remain durable for only half of patients. This review covers PCNSL presentation, evaluation, and treatment in immunocompetent individuals.

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.6K
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.7K

Related Experiment Videos

Last Updated: Feb 27, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

18.7K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.6K
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.7K

Area of Science:

  • Oncology
  • Neurology
  • Hematology

Background:

  • Primary CNS lymphoma (PCNSL) is a rare non-Hodgkin lymphoma affecting the brain, eyes, and cerebrospinal fluid.
  • High-dose methotrexate has improved prognosis, yet treatment durability and late neurotoxicity remain challenges.

Purpose of the Study:

  • To provide an overview of the presentation, evaluation, and treatment of primary CNS lymphoma in immunocompetent patients.
  • To highlight the limited number of randomized trials and unanswered questions regarding optimal first-line and salvage therapies for PCNSL.

Main Methods:

  • Literature review of primary CNS lymphoma, focusing on clinical presentation, diagnostic evaluation, and therapeutic strategies.
  • Analysis of existing clinical trials and treatment outcomes for immunocompetent PCNSL patients.

Main Results:

  • High-dose methotrexate has become a cornerstone in PCNSL treatment, improving survival rates.
  • Durable responses are achieved in approximately 50% of patients, with significant concerns regarding long-term neurotoxicity.

Conclusions:

  • Despite advances, optimal treatment strategies for PCNSL, particularly for recurrent or refractory disease, require further investigation.
  • A comprehensive understanding of PCNSL presentation, evaluation, and current treatment options is crucial for managing this rare malignancy.